State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk (NYSE: NVO )'s Wegovy or Eli Lilly (NYSE: LLY )'s Zepbound, ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

The yield has risen 73.6 basis points over the past seven weeks, according to Dow Jones Market Data. On Friday, traders were ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.